-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to statistics, the Chinese pharmaceutical market is expected to grow to US$145 billion by 2022
.
In this regard, the industry analysts believe that China's pharmaceutical industry will further release the demand for pharmaceutical equipment under the accelerated development mode, and this will also inject sustained growth momentum into the development of the pharmaceutical equipment industry
.
In fact, in the highly prosperous pharmaceutical market, there are early signs that the pharmaceutical equipment industry will continue to develop well
.
It is understood that the performance of some pharmaceutical machinery companies has increased significantly since the beginning of this year
.
According to the first three quarterly reports of 2021, the net profit of Chutian Technology, Dongfulong, and Canaan Technology was 401 million yuan (+723.
53%), 558 million (+93.
69%), and 57.
682 million yuan (+10.
63%), respectively.
Compared with 2020, the net profit of Chutian Technology and Tofflon in the first three quarters of this year has exceeded the data of the whole year of last year
.
In addition, in terms of revenue, some companies also performed very well
.
Among them, Tofflon's total revenue in 2020 is 2.
71 billion yuan, and the company's revenue in the first three quarters of this year has reached 2.
882 billion yuan
.
Chutian Technology generated 3.
682 billion yuan in operating income in the first three quarters, which also exceeded the 3.
576 billion yuan in the whole year of last year
.
With the favorable pharmaceutical environment and the continuous optimization of the pharmaceutical competition landscape, the industry expects that the performance of pharmaceutical equipment companies will continue to grow in the future
.
It is worth mentioning that the current process of domestically replacing imports has begun to accelerate under the support of the policy of preferential procurement of domestically-made equipment
.
In this context, analysts pointed out that while the performance of pharmaceutical machinery companies continues to grow, they will also accelerate their development in the direction of high quality
.
Under the background that the domestic pharmaceutical industry continues to develop towards high quality through innovation and upgrading, the competitiveness of domestic pharmaceutical equipment companies will continue to increase, and more domestic and foreign customers will be favored and praised
.
In addition to the continued growth of performance, industry insiders believe that in the future, the investment of pharmaceutical machinery companies will also continue to expand in terms of R&D investment.
.
It is understood that in 2020, Tofflon’s R&D investment has reached 156 million yuan, accounting for 5.
77% of operating income
.
The R&D expenses in the first three quarters of this year were 166 million yuan, which has exceeded the R&D expenses for the whole year of last year; Chutian Technology will invest 288 million yuan in R&D in 2020, and R&D investment will account for 8.
05% of revenue
.
By this year, the company's R&D expenses in the first three quarters reached 307 million yuan, a year-on-year increase of 60.
7%
.
From the above-mentioned pharmaceutical machinery companies' performance, R&D investment in the first half of the year, the continuous growth of R&D investment, and the overall action and measures taken during the reporting period, industry analysis believes that the development status and trends of the domestic pharmaceutical equipment industry can be glimpsed
.
First of all, in the context of increasing R&D investment in recent years, the driving force for the development of innovative pharmaceutical machine companies has become a consensus
.
In the future, pharmaceutical machinery companies will continue to develop new technologies and products, innovate, improve and upgrade existing equipment according to industry and customer needs
.
In addition, with continuous innovation, the substitution of imported domestic pharmaceutical machines will also accelerate
.
It is reported that the current process of replacing imports with domestic products has begun to accelerate under the support of the policy of preferential procurement of domestically produced equipment
.
Take Chutian Technology as an example.
When it was surveyed by an institution earlier, it stated that the company had been deploying import substitution in the high-end market of vaccine products three years ago, and the product performance and quality have been able to meet the needs of high-end customers; Entered the high-end vaccine industry supply chain and competed on the same platform with imported equipment
.
In general, judging from the current industry development trend, the pharmaceutical equipment industry will continue to develop in 2022, and related pharmaceutical companies will also have more opportunities
.
It is worth noting that in order to seize the opportunity, many pharmaceutical machinery companies have gone all out to catch up with production and project progress, and set development goals for next year
.
For example, Chutian Technology has stated that in the next phase, it will focus on both products and the market, and plan to increase revenue and net profit next year by no less than 20% compared with 2021; Tofflon also stated that it will continue to deepen the international market and strengthen new products.
Steadily increase its market share in the international market; In addition, Tailin Biology plans to carry out localized substitution of high-end instruments and equipment, and participate in international high-end competition, etc.
.
.
In this regard, the industry analysts believe that China's pharmaceutical industry will further release the demand for pharmaceutical equipment under the accelerated development mode, and this will also inject sustained growth momentum into the development of the pharmaceutical equipment industry
.
In fact, in the highly prosperous pharmaceutical market, there are early signs that the pharmaceutical equipment industry will continue to develop well
.
It is understood that the performance of some pharmaceutical machinery companies has increased significantly since the beginning of this year
.
According to the first three quarterly reports of 2021, the net profit of Chutian Technology, Dongfulong, and Canaan Technology was 401 million yuan (+723.
53%), 558 million (+93.
69%), and 57.
682 million yuan (+10.
63%), respectively.
Compared with 2020, the net profit of Chutian Technology and Tofflon in the first three quarters of this year has exceeded the data of the whole year of last year
.
In addition, in terms of revenue, some companies also performed very well
.
Among them, Tofflon's total revenue in 2020 is 2.
71 billion yuan, and the company's revenue in the first three quarters of this year has reached 2.
882 billion yuan
.
Chutian Technology generated 3.
682 billion yuan in operating income in the first three quarters, which also exceeded the 3.
576 billion yuan in the whole year of last year
.
With the favorable pharmaceutical environment and the continuous optimization of the pharmaceutical competition landscape, the industry expects that the performance of pharmaceutical equipment companies will continue to grow in the future
.
It is worth mentioning that the current process of domestically replacing imports has begun to accelerate under the support of the policy of preferential procurement of domestically-made equipment
.
In this context, analysts pointed out that while the performance of pharmaceutical machinery companies continues to grow, they will also accelerate their development in the direction of high quality
.
Under the background that the domestic pharmaceutical industry continues to develop towards high quality through innovation and upgrading, the competitiveness of domestic pharmaceutical equipment companies will continue to increase, and more domestic and foreign customers will be favored and praised
.
In addition to the continued growth of performance, industry insiders believe that in the future, the investment of pharmaceutical machinery companies will also continue to expand in terms of R&D investment.
.
It is understood that in 2020, Tofflon’s R&D investment has reached 156 million yuan, accounting for 5.
77% of operating income
.
The R&D expenses in the first three quarters of this year were 166 million yuan, which has exceeded the R&D expenses for the whole year of last year; Chutian Technology will invest 288 million yuan in R&D in 2020, and R&D investment will account for 8.
05% of revenue
.
By this year, the company's R&D expenses in the first three quarters reached 307 million yuan, a year-on-year increase of 60.
7%
.
From the above-mentioned pharmaceutical machinery companies' performance, R&D investment in the first half of the year, the continuous growth of R&D investment, and the overall action and measures taken during the reporting period, industry analysis believes that the development status and trends of the domestic pharmaceutical equipment industry can be glimpsed
.
First of all, in the context of increasing R&D investment in recent years, the driving force for the development of innovative pharmaceutical machine companies has become a consensus
.
In the future, pharmaceutical machinery companies will continue to develop new technologies and products, innovate, improve and upgrade existing equipment according to industry and customer needs
.
In addition, with continuous innovation, the substitution of imported domestic pharmaceutical machines will also accelerate
.
It is reported that the current process of replacing imports with domestic products has begun to accelerate under the support of the policy of preferential procurement of domestically produced equipment
.
Take Chutian Technology as an example.
When it was surveyed by an institution earlier, it stated that the company had been deploying import substitution in the high-end market of vaccine products three years ago, and the product performance and quality have been able to meet the needs of high-end customers; Entered the high-end vaccine industry supply chain and competed on the same platform with imported equipment
.
In general, judging from the current industry development trend, the pharmaceutical equipment industry will continue to develop in 2022, and related pharmaceutical companies will also have more opportunities
.
It is worth noting that in order to seize the opportunity, many pharmaceutical machinery companies have gone all out to catch up with production and project progress, and set development goals for next year
.
For example, Chutian Technology has stated that in the next phase, it will focus on both products and the market, and plan to increase revenue and net profit next year by no less than 20% compared with 2021; Tofflon also stated that it will continue to deepen the international market and strengthen new products.
Steadily increase its market share in the international market; In addition, Tailin Biology plans to carry out localized substitution of high-end instruments and equipment, and participate in international high-end competition, etc.
.
